Eli Lilly's Future Outlook: A Comprehensive Analysis
Eli Lilly, the top healthcare stock with a valuation of $550 billion, is expected to focus on the weight-loss market, which is projected to be worth nearly $300 billion by 2030. With its approved weight-loss treatment Zepbound and ongoing development of a once-daily weight-loss pill, Eli Lilly aims to capture a significant share of this market. The company's annual sales could potentially exceed $50 billion in five years, driven by the success of Zepbound and other growth catalysts in its portfolio. There is a possibility that Eli Lilly could become the first healthcare company to reach a $1 trillion market cap, making it an attractive investment opportunity.